, Volume 41, Issue 2, pp 517–523

Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia

  • A. T. Griffin
  • P. Peyrani
  • T. L. Wiemken
  • J. A. Ramirez
  • F. W. Arnold
Clinical and Epidemiological Study



The Infectious Diseases Society of America has recommended empiric therapy active against methicillin-resistant Staphylococcus aureus (MRSA) for all community-acquired pneumonia (CAP) patients admitted to the intensive care unit (ICU). However, there is sparse data to support this recommendation. The objective of our study was to ascertain if such a practice improves outcomes.


This study was a secondary, retrospective analysis of the Community-Acquired Pneumonia Organization (CAPO) international database on CAP. Outcomes in patients admitted to the ICU were compared according to empiric initiation of anti-MRSA therapy (vancomycin or linezolid) with standard ICU CAP therapy (MRSA therapy group) or standard therapy alone for ICU CAP (standard therapy group).


A total of 621 patients were identified with ICU pneumonia, of whom 57 patients had been initiated empirically on vancomycin or linezolid (MRSA therapy group). Patients of the MRSA therapy group had more comorbidities and were more severely ill than those of the standard therapy group. However, there were no statistical differences between the MRSA therapy group and standard therapy group for the primary outcomes of in-hospital and 28-day mortality, length of stay and time to clinical stability.


These findings suggest that empiric MRSA therapy in all ICU CAP patients may not improve outcomes and argue for clinician review of local epidemiologic trends on MRSA prevalence to ascertain the need for empiric MRSA coverage.


MRSA Community-acquired pneumonia Intensive care 


  1. 1.
    Rubinstein E, Kollef M, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46:S378–85.PubMedCrossRefGoogle Scholar
  2. 2.
    Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton–Valentine leukocidin genes. Clin Infect Dis. 1997;40:100–7.CrossRefGoogle Scholar
  3. 3.
    Brulé N, Jaffré S, Chollet S, Germaud P, Chailleux E. Necrotizing pneumonia due to Staphylococcus aureus producing Panton-Valentine toxin. Rev Mal Respir. 2008;25:875–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Lobo L, Reed K, Wunderink R. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest. 2010;138:130–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Salgado CD, Farr BM, Calfee DM. Community-acquired methicillin resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis. 2003;36:131–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Faria NA, Oliveira DC, Westh H. Epidemiology of emerging methicillin-resistant Staphylococcus aureus (MRSA) in Denmark: a nationwide study in a country with low prevalence of MRSA infection. J Clin Microbiol. 2005;43:1836–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Thomas R, Ferguson J, Coombs G, Gibson PG. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia: a clinical audit. Respirology. 2011;16:926–31.PubMedCrossRefGoogle Scholar
  8. 8.
    Li HT, Zhang TT, Huang J, Zhou YQ, Zhu JX, Wu BQ. Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients. Respiration. 2011;81:448–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Woodhead M, Blasi F, Ewig S, Garau J, et al. Guidelines for the management of adult lower respiratory tract infections-summary. Clin Microbiol Infect. 2011;17:1–24.PubMedCrossRefGoogle Scholar
  10. 10.
    Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:e18–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Lim WS, van der Eerden MM, Laing R, et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82.PubMedCrossRefGoogle Scholar
  13. 13.
    Imai K, van Dyk D. Causal inference with general treatment regimes: generalizing the propensity score. J Am Stat Assoc. 2004;99:854–66.CrossRefGoogle Scholar
  14. 14.
    Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008;133:610–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest. 2000;118:1344–54.PubMedCrossRefGoogle Scholar
  17. 17.
    Frei CR, Attridge RT, Mortensen EM, et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Ther. 2010;32:293–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America; American thoracic society. Infectious diseases society of America/American thoracic society guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.PubMedCrossRefGoogle Scholar
  19. 19.
    Bodí M, Rodríguez A, Solé-Violán J, et al. Community-acquired pneumonia intensive care units (CAPUCI) study investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to infectious diseases society of America guidelines on survival. Clin Infect Dis. 2005;14:1709–16.CrossRefGoogle Scholar
  20. 20.
    Soavi L, Signorini L, Stellini R, et al. Linezolid and clindamycin improve the outcome of severe, necrotizing pneumonia due to community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). Infez Med. 2011;19:42–4.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • A. T. Griffin
    • 1
  • P. Peyrani
    • 1
  • T. L. Wiemken
    • 1
  • J. A. Ramirez
    • 1
  • F. W. Arnold
    • 1
  1. 1.Department of Medicine, Division of Infectious DiseasesUniversity of LouisvilleLouisvilleUSA

Personalised recommendations